More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report

• Autor(a) principal: Yuan,J.L.
• Data de Publicação: 2015
• Outros Autores: Wang,F.L., Yi,X.M., Qin,W.J., Wu,G.J., Huan,Y., Yang,L.J., Zhang,G., Yu,L., Zhang,Y.T., Qin,R.L., Tian,C.J.
• Tipo de documento: Relatório
• Idioma: eng
• Título da fonte: Brazilian Journal of Medical and Biological Research
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000100034
• topic: Metastatic renal cell carcinoma; Sequential therapy; Targeted anticancer agents; Sorafenib; Sunitinib; Immunotherapy

Although radical nephrectomy alone is widely accepted as the standard of care in localized treatment for renal cell carcinoma (RCC), it is not sufficient for the treatment of metastatic RCC (mRCC), which invariably leads to an unfavorable outcome despite the use of multiple therapies. Currently, sequential targeted agents are recommended for the management of mRCC, but the optimal drug sequence is still debated. This case was a 57-year-old man with clear-cell mRCC who received multiple therapies following his first operation in 2003 and has survived for over 10 years with a satisfactory quality of life. The treatments given included several surgeries, immunotherapy, and sequentially administered sorafenib, sunitinib, and everolimus regimens. In the course of mRCC treatment, well-planned surgeries, effective sequential targeted therapies and close follow-up are all of great importance for optimal management and a satisfactory outcome.